Effects of lorcaserin on fat and lean mass loss in obese and overweight patients without and with type 2 diabetes mellitus: the BLOSSOM and BLOOM-DM studies
Effects of lorcaserin on fat and lean mass loss in obese and overweight patients without and with type 2 diabetes mellitus: the BLOSSOM and BLOOM-DM studies
复制标题
DOI：
10.1111/dom.12690
复制
发表时间：
2016-09-01
影响因子：
5.8
通讯作者：
Rubino, D.
中科院分区：
文献类型：
--
作者：
Apovian, C.;Palmer, K.;Rubino, D.
在一部分未患（BLOSSOM研究）和患有（BLOOM - DM研究）2型糖尿病的患者中，使用双能X线吸收法（DXA）测定身体成分，这些患者接受饮食和运动咨询，同时每日两次服用10mg氯卡色林或安慰剂。在研究第1天（基线）、第24周和第52周进行DXA扫描。亚群（无糖尿病，n = 189；有糖尿病，n = 63）的基线人口统计学特征在各项研究之间相似，且能代表其研究人群。在第52周，服用氯卡色林的无糖尿病患者相较于服用安慰剂的患者，脂肪量减少明显更多（-12.06%对 -5.93%；p = 0.008）。在患有糖尿病的患者中，与安慰剂相比，氯卡色林也使脂肪量减少（-9.87%对 -1.65%；p < 0.05）。与安慰剂相比，氯卡色林使躯干部位的脂肪量减少更多（无糖尿病：-3.31%对 -2.05%；有糖尿病：-3.65%对 -0.36%）。氯卡色林导致的体重减轻与脂肪量减少的程度比瘦肉量减少的程度更大，并且无糖尿病和有糖尿病患者所减少的大部分脂肪量都来自身体的中心区域。
Body composition was determined using dual-energy X-ray absorptiometry (DXA) in a subset of patients without (BLOSSOM) and with (BLOOM-DM) type 2 diabetes who received diet and exercise counselling along with either lorcaserin 10 mg twice daily or placebo. DXA scans were performed on study day 1 (baseline), week 24 and week 52. Baseline demographics of the subpopulations (without diabetes, n = 189; with diabetes, n = 63) were similar between studies and representative of their study populations. At week 52, patients without diabetes on lorcaserin lost significantly more fat mass relative to those on placebo (-12.06% vs -5.93%; p = 0.008). In patients with diabetes, fat mass was also decreased with lorcaserin relative to placebo (-9.87% vs -1.65%; p < 0.05). More fat mass was lost in the trunk region with lorcaserin compared with placebo (without diabetes: -3.31% vs -2.05%; with diabetes: -3.65% vs -0.36%). Weight loss with lorcaserin was associated with a greater degree of fat mass loss than lean mass loss, and most of the fat mass lost for patients without and with diabetes was from the central region of the body.